Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.

Name: Kaimen Rigor review — Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.
Item: Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.
Rating: 100
Author: Alpha1

Qin J, Xue L, Hao A, Guo X, Jiang T, Ni Y, Liu S, Chen Y, Jiang H, Zhang C, Kang M, Lin J, Li H, Li C, Tian H, Li L, Fu J, Zhang Y, Ma J, Wang X, Fu M, Yang H, Yang Z, Han Y, Chen L, Tan L, Dai T, Liao Y, Zhang W, Li B, Chen Q, Guo S, Qi Y, Wei L, Li Z, Tian Z, Kang X, Zhang R, Li Y, Wang Z, Chen X, Hou Z, Zheng R, Zhu W, He J, Li Y

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 2.75★ (Weak), 0 critical, 3 high issues for “Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Read alongside

Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.

Read full text (PMC)

DOI

10.1038/s41591-024-03064-w

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/49de7a8e-b37a-4c69-82e5-ab2d53e60682" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/49de7a8e-b37a-4c69-82e5-ab2d53e60682/badge" alt="Kaimen Rigor review — 2.75★ (Weak), 0 critical, 3 high issues for “Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

a36874ce9013d3383fd38c49a38fcce05f2430258e27ce4d75cd29823d78d11d

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.

Paper source

Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is based on pathological complete response (pCR) rate, a surrogate endpoint. The paper does not demonstrate target engagement at the tested dose (no PK/PD data) and does not cite validated evidence linking pCR to the clinical outcome (EFS/OS) in this setting. The authors acknowledge EFS is not mature and that survival outcomes remain the gold standard.
“The dual primary endpoints were the rate of pathological complete response (pCR)... and event-free survival (EFS)... This study reports the final analysis of pCR rates.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect is a pCR rate of 28.0% in the Cam+nab-TP group vs 4.7% in the TP group, and 15.4% in the Cam+TP group. While statistically significant, the clinical meaningfulness is not anchored to a validated minimal clinically important difference or long-term survival benefit. The authors note EFS is not mature and that pCR is a surrogate.
“The Cam+nab-TP and Cam+TP groups exhibited significantly higher pCR rates of 28.0% and 15.4%, respectively, compared to 4.7% in the TP group... The study met its primary endpoint of pCR; however, EFS is not yet mature.”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 103AuthenticityData authenticity concerns 04DisclosureNone found 105AvailabilityBroken references and links 06Copyedit5 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This phase 3 trial is methodologically rigorous with a well-justified scientific premise, robust study design, and transparent reporting. Minor gaps include the lack of an explicit statement of adherence to a reporting guideline (CONSORT) and a regulatory compliance framework (Declaration of Helsinki), and a few copyedit issues.

Both independent reviewers agreed on all dimensions and study type (interventional). The evaluation covered the full text. The statistics verification checked only 2 tests (those with test statistics or effect estimates with CIs); all other statistical claims are unverified. The citation check found 1 reference not found in the registry (flagged below).

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Overstated conclusions

3 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

5 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

1 finding · worst low

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

2 integrity concerns flagged (0 high).

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction cites multiple prior studies (e.g., ESCORT, ESCORT-1st, phase 1b/2 trials) and discusses their limitations, including the lack of phase 3 confirmatory data. The rationale for comparing camrelizumab plus chemotherapy versus chemotherapy alone is logically derived from these prior findings. The paper also addresses limitations of prior research, such as the need for phase 3 validation and the choice of chemotherapy backbone.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior phase 1b/2 trials and retrospective analyses, and clearly rationalizes the need for a phase 3 confirmatory study.

Evidence

“Several phase 1b and 2 trials assessing neoadjuvant immunotherapy with camrelizumab and chemotherapy for LA-ESCC report high pathological complete response (pCR) rates of 17.6% to 39.2%”

Introduction ¶2Find in source

“Despite these promising results, there remains a lack of phase 3 confirmatory studies to further validate these findings.”

Introduction ¶2Find in source

“Against this backdrop, we initiated the ESCORT-NEO/NCCES01 study, a phase 3, open-label, randomized trial aimed at assessing the efficacy and safety of neoadjuvant camrelizumab plus either TP or nab-TP, as compared to TP alone, in patients with resectable LA-ESCC.”

Introduction ¶3Find in source

PASSReviewer 2· 90% conf

The paper establishes a strong scientific premise by citing prior phase 1b/2 trials and retrospective analyses, and clearly rationalizes the need for a phase 3 confirmatory study.

Evidence

“Several phase 1b and 2 trials assessing neoadjuvant immunotherapy with camrelizumab and chemotherapy for LA-ESCC report high pathological complete response (pCR) rates of 17.6% to 39.2%”

Introduction ¶2Find in source

“Despite these promising results, there remains a lack of phase 3 confirmatory studies to further validate these findings.”

Introduction ¶2Find in source

“This preference for nab-paclitaxel, especially when combined with immunotherapy in LA-ESCC, is supported by several phase 2 studies”

Introduction ¶3Find in source

Randomization method is described (randomized trial management system) and stratified by clinical stage. The unit of randomization is the patient. Blinding is not applicable as the trial is open-label, but this is stated and a rationale is implied (non-blinded design noted as a limitation). Power analysis is detailed with assumptions and alpha levels. Inclusion/exclusion criteria are extensive and prespecified. Outlier handling is addressed through ITT and safety set definitions. Controls are the TP group (chemotherapy alone). Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial design is rigorous with clear randomization, stratification, and prespecified endpoints, though blinding is not applicable due to the open-label design.

Evidence

“Eligible patients were randomly assigned in a 1:1:1 ratio to either the Cam+nab-TP group, the Cam+TP group, or the TP group using the randomized trial management system. Randomization was stratified according to clinical stage into I/II, III, and IVA.”

MethodsFind in source

“Assuming pCR rates of 30% for the Cam+nab-TP group, 25% for the Cam+TP group and 9% for the TP group, and using a 1:1:1 randomization ratio with an α level set at 0.005 (one-sided), it was calculated that 111 patients per group would provide at least 93% power to establish the superiority of the Cam+nab-TP group over the TP group”

Statistical analysisFind in source

“Moreover, the non-blinded design of this study could introduce some degree of bias.”

LimitationsFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous: randomized, stratified, with a prespecified sample size calculation, clear inclusion/exclusion criteria, and a defined analysis population.

Evidence

MethodsFind in source

Statistical analysisFind in source

“Moreover, the non-blinded design of this study could introduce some degree of bias.”

LimitationsFind in source

Sex is reported for all participants (84.9% male), and both sexes were eligible. Age is reported with median and range. Health status is captured via ECOG PS and inclusion/exclusion criteria. Demographics include age, sex, and clinical stage. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables are well reported for a human trial, including sex, age, and clinical characteristics; species/strain and housing are not applicable.

Evidence

“The median age of all patients was 63 years (range, 44–75), with 84.9% being male.”

ResultsFind in source

“Median (range) | 63 (45–75) | 63 (44–75) | 65 (44–75)”

Table 1Find in source

“Among these patients, 6 (1.5%) were in clinical stage I (all cT1N1), 100 (25.6%) were stage II, 279 (71.4%) were stage III and 6 (1.5%) were stage IVA.”

ResultsFind in source

PASSReviewer 2· 90% conf

Sex, age, and clinical characteristics are reported in detail; demographics are comprehensive.

Evidence

paraphrase[Table 1]

“Sex, n (%) | Male | 116 (87.9) | 112 (86.2) | 104 (80.6)”

“The median age of all patients was 63 years (range, 44–75), with 84.9% being male.”

ResultsFind in source

paraphrase[Table 1]

“ECOG PS, n (%) | 0 | 105 (79.5) | 106 (81.5) | 104 (80.6)”

The study protocol was approved by the Ethics Committee of the National Cancer Center and multiple other institutional ethics committees (listed). All enrolled patients provided written informed consent. The study was registered before enrollment (ChiCTR2000040034). Regulatory compliance is not explicitly named (e.g., Declaration of Helsinki), but the detailed ethics approval and consent process are adequate.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals are thoroughly documented with named ethics committees and informed consent; regulatory compliance is implied.

Evidence

paraphrase[Methods, Study design and patients]

“The study protocol was approved by the Ethics Committee of the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Anyang Cancer Hospital; ...”

“All enrolled patients provided written informed consent.”

MethodsFind in source

“The study was registered before patient enrollment ( ChiCTR2000040034 (https://www.chictr.org.cn/showproj.html?proj=64180) ).”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethics approval from named committees and written informed consent are documented; trial registration is provided.

Evidence

paraphrase[Methods, Study design and patients]

“All enrolled patients provided written informed consent.”

MethodsFind in source

“Chinese Clinical Trial Registry identifier: ChiCTR2000040034”

AbstractFind in source

The investigational products (camrelizumab, paclitaxel, nab-paclitaxel, cisplatin) are identified with doses and regimens. The PD-L1 IHC 22C3 pharmDx kit (Dako) is specified. Statistical software (SAS 9.4) and sample size software (NCSS&PASS 15.0) are identified. Antibodies, cell lines, and mycoplasma testing are not applicable as this is a clinical trial without wet-lab assays.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Key resources are adequately identified: investigational drugs are named with doses, and the PD-L1 IHC kit is specified; software is identified.

Evidence

“The Cam+nab-TP group received camrelizumab (200 mg on day 1), albumin-bound paclitaxel (125 mg/m² on days 1 and 8), and cisplatin (75 mg/m² on day 1).”

MethodsFind in source

“PD-L1 expression levels at a central laboratory via immunohistochemistry (PD-L1 IHC 22C3 pharmDx kit, Dako).”

MethodsFind in source

“All statistical analyses were conducted using SAS software version 9.4.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational products (camrelizumab, paclitaxel, nab-paclitaxel, cisplatin) are identified with doses and regimens; PD-L1 IHC kit is specified.

Evidence

“The Cam+nab-TP group received camrelizumab (200 mg on day 1), albumin-bound paclitaxel (125 mg/m² on days 1 and 8), and cisplatin (75 mg/m² on day 1).”

MethodsFind in source

“PD-L1 expression levels at a central laboratory via immunohistochemistry (PD-L1 IHC 22C3 pharmDx kit, Dako).”

MethodsFind in source

“All statistical analyses were conducted using SAS software version 9.4.”

Statistical analysisFind in source

Statistical tests are named (Cochran-Mantel-Haenszel test, Mantel-Haenszel method for differences/ORs). Assumptions are addressed through stratification and prespecified analysis. Exact p-values are reported (e.g., P < 0.0001, P = 0.0034). Effect sizes with confidence intervals are provided. Software is identified. Data presentation includes per-group n and confidence intervals. Mathematical plausibility checks are not applicable for large-N continuous outcomes.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and confidence intervals; assumptions are handled by design.

Evidence

“The pCR between Cam+nab-TP and TP groups as well as between Cam+TP and TP groups were compared by using stratified Cochran-Mantel-Haenszel test with the same stratification factor.”

Statistical analysisFind in source

“P < 0.0001; Cam+TP versus TP: difference 10.9%, 95% CI 3.7–18.1, P = 0.0034”

ResultsFind in source

“difference 23.5%, 95% confidence interval (CI), 15.1–32.0; odds ratio (OR), 8.11; 95% CI, 3.28–20.06”

ResultsFind in source

PASSReviewer 2· 90% conf

Statistical tests are named, p-values are exact, effect sizes with CIs are reported, and software is identified; data presentation follows clinical trial norms.

Evidence

“The pCR between Cam+nab-TP and TP groups as well as between Cam+TP and TP groups were compared by using stratified Cochran-Mantel-Haenszel test”

Statistical analysisFind in source

“P < 0.0001; Cam+TP versus TP: difference 10.9%, 95% CI 3.7–18.1, P = 0.0034”

ResultsFind in source

“difference 23.5%, 95% confidence interval (CI), 15.1–32.0; odds ratio (OR), 8.11; 95% CI, 3.28–20.06”

ResultsFind in source

The data availability statement provides a concrete route: individual deidentified participant data can be requested 24 months after study completion via proposal to the corresponding author, with review and data access agreement. This is a managed-access mechanism, which is adequate for patient-level data. Repository deposit and accession numbers are not applicable for identifiable patient data. Code sharing is not applicable as no custom code was used.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is adequately described with a managed-access mechanism; code sharing is not applicable as no custom code was used.

Evidence

“Due to intellectual property and confidentiality obligations, individual deidentified participant data that underlie the results reported in this article can be requested 24 months after study completion. Qualified researchers must submit a proposal to the corresponding author at liyin@cicams.ac.cn, outlining the reasons for requesting the data.”

Data availabilityFind in source

“No custom code was used for data analysis in this study.”

Data availabilityFind in source

PASSReviewer 2· 90% conf

Data availability statement provides a concrete managed-access route; protocol and SAP are available; no custom code was used.

Evidence

“individual deidentified participant data that underlie the results reported in this article can be requested 24 months after study completion. Qualified researchers must submit a proposal to the corresponding author at liyin@cicams.ac.cn”

Data availabilityFind in source

“The study protocol and statistical analysis plan are available alongside the published article.”

Data availabilityFind in source

“No custom code was used for data analysis in this study.”

Data availabilityFind in source

Methods are comprehensive and replicable. The trial is registered (ChiCTR2000040034). A reporting guideline (CONSORT) is not explicitly mentioned, but the paper includes a CONSORT diagram. All prespecified outcomes are reported (pCR and EFS, with EFS noted as immature). Limitations are thoroughly discussed. Conclusions are proportional to the evidence. Funding and competing interests are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Reporting is transparent with detailed methods, trial registration, and discussion of limitations; reporting guideline adherence is implied but not explicitly stated.

Evidence

“Chinese Clinical Trial Registry identifier: ChiCTR2000040034”

AbstractFind in source

“This study has several limitations. First, this study did not directly compare the two neoadjuvant chemotherapy regimens combined with camrelizumab that were tested.”

LimitationsFind in source

paraphrase[Acknowledgements and Competing interests]

“This study was funded by Jiangsu Hengrui Pharmaceuticals. ... Z.H., R. Zheng and W.Z. are employees of Jiangsu Hengrui Pharmaceuticals.”

PASSReviewer 2· 90% conf

Methods are detailed, trial is registered, limitations are discussed, conclusions are proportional, and funding/COI are disclosed.

Evidence

“Chinese Clinical Trial Registry identifier: ChiCTR2000040034”

AbstractFind in source

“This study has several limitations. First, this study did not directly compare the two neoadjuvant chemotherapy regimens combined with camrelizumab that were tested.”

LimitationsFind in source

paraphrase[Acknowledgements and Competing interests]

“This study was funded by Jiangsu Hengrui Pharmaceuticals. ... Z.H., R. Zheng and W.Z. are employees of Jiangsu Hengrui Pharmaceuticals.”

Registered (2 IDs: ClinicalTrials.gov, Chinese Clinical Trial Registry). Reporting guideline cited: CONSORT.

Broken references and links

1 finding · worst low

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

Checked 51 references by DOI: 50 verified — 1 DOI unresolved.

2 data/code links checked; 2 live.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly clarity, grammar, consistency.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published paper is robust and methodologically sound. An informed reader should note the minor gaps (no explicit CONSORT or Declaration of Helsinki statement) and the one reference not found in the registry, but these do not undermine the core findings. No erratum or correction is warranted based on this audit.

1.
HIGHreporting
Add an explicit statement of adherence to CONSORT reporting guidelines in the Methods or a dedicated Reporting Summary section.
Both reviewers noted that a reporting guideline is not explicitly mentioned, which is a standard expectation for a phase 3 trial.
2.
HIGHethics
Add a statement of regulatory compliance (e.g., Declaration of Helsinki) in the Methods section.
Both reviewers flagged that regulatory compliance is not explicitly stated, which is a minor but common reporting gap.
3.
HIGHreporting
Verify the reference 'Chinese Guidelines on Perioperative Management of Resectable Esophageal Cancer (2023 edition)' (DOI: 10.3760/cma.j.cn112137-20230604-00933) that was not found in the registry; correct or replace it if necessary.
A reference not found in any registry may be fabricated or have an incorrect DOI; this is a potential integrity concern.
4.
MEDIUMcopyedit
Remove the erroneous URL link to UniProt (https://www.uniprot.org/uniprot/T3N0M0) in the Methods, Study design and patients section.
The URL is irrelevant and likely a formatting error; it could confuse readers.
5.
MEDIUMcopyedit
Standardize the formatting of '95% CI' vs '95% confidence interval' throughout the manuscript (e.g., in the Abstract).
Minor formatting inconsistency that can be easily harmonized.
6.
MEDIUMcopyedit
Rephrase 'The impact of pCR varies across different neoadjuvant regimens' to 'The impact of pCR varies among different neoadjuvant regimens' in the Discussion.
Minor grammatical improvement for clarity.
7.
MEDIUMreporting
Clarify the manufacturer/source of camrelizumab in the Methods (e.g., Jiangsu Hengrui Pharmaceuticals).
One reviewer noted that the source of the investigational product is not explicitly stated in the text, though it is implied by the sponsor.
8.
MEDIUMreporting
Provide the specific version of the PD-L1 IHC 22C3 pharmDx kit and any validation data in the Methods.
One reviewer suggested improving key_resources reporting by including version and validation details.
9.
MEDIUMreporting
Add a statement on the handling of missing data for PD-L1 status (e.g., imputation or sensitivity analysis) in the Statistical analysis section.
One reviewer noted that missing data handling for PD-L1 is not addressed, which could affect subgroup analyses.
10.
LOWreporting
Consider providing a direct comparison between Cam+nab-TP and Cam+TP groups as a prespecified exploratory analysis to address the limitation noted in the Discussion.
The authors themselves note this as a limitation; a prespecified exploratory analysis would strengthen the paper.
11.
LOWreporting
In the Discussion, explicitly acknowledge that the pCR endpoint is a surrogate and that EFS/OS are needed to confirm clinical benefit.
One reviewer suggested making this point more prominent to temper conclusions.
12.
LOWdata code
Consider adding a data-sharing statement that includes an expected date for data availability (e.g., '24 months after study completion, expected by [date]').
One reviewer noted that the timeline is vague without a specific date.

Full text (64,505 chars)Analyzed: Aug 16, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.

Read full text (PMC)

DOI

10.1038/s41591-024-03064-w

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/49de7a8e-b37a-4c69-82e5-ab2d53e60682" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/49de7a8e-b37a-4c69-82e5-ab2d53e60682/badge" alt="Kaimen Rigor review — 2.75★ (Weak), 0 critical, 3 high issues for “Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

a36874ce9013d3383fd38c49a38fcce05f2430258e27ce4d75cd29823d78d11d

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is based on pathological complete response (pCR) rate, a surrogate endpoint. The paper does not demonstrate target engagement at the tested dose (no PK/PD data) and does not cite validated evidence linking pCR to the clinical outcome (EFS/OS) in this setting. The authors acknowledge EFS is not mature and that survival outcomes remain the gold standard.
“The dual primary endpoints were the rate of pathological complete response (pCR)... and event-free survival (EFS)... This study reports the final analysis of pCR rates.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The reported effect is a pCR rate of 28.0% in the Cam+nab-TP group vs 4.7% in the TP group, and 15.4% in the Cam+TP group. While statistically significant, the clinical meaningfulness is not anchored to a validated minimal clinically important difference or long-term survival benefit. The authors note EFS is not mature and that pCR is a surrogate.
“The Cam+nab-TP and Cam+TP groups exhibited significantly higher pCR rates of 28.0% and 15.4%, respectively, compared to 4.7% in the TP group... The study met its primary endpoint of pCR; however, EFS is not yet mature.”
Find in source

Findings by category

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Overstated conclusions

3 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

5 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

1 finding · worst low

Other integrity concernAssessed

2 integrity concerns flagged (0 high).

Reporting gaps

None found

Checked — nothing surfaced.

Eight Dimensions8 pass

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior phase 1b/2 trials and retrospective analyses, and clearly rationalizes the need for a phase 3 confirmatory study.

Evidence

“Several phase 1b and 2 trials assessing neoadjuvant immunotherapy with camrelizumab and chemotherapy for LA-ESCC report high pathological complete response (pCR) rates of 17.6% to 39.2%”

Introduction ¶2Find in source

“Despite these promising results, there remains a lack of phase 3 confirmatory studies to further validate these findings.”

Introduction ¶2Find in source

Introduction ¶3Find in source

PASSReviewer 2· 90% conf

The paper establishes a strong scientific premise by citing prior phase 1b/2 trials and retrospective analyses, and clearly rationalizes the need for a phase 3 confirmatory study.

Evidence

“Several phase 1b and 2 trials assessing neoadjuvant immunotherapy with camrelizumab and chemotherapy for LA-ESCC report high pathological complete response (pCR) rates of 17.6% to 39.2%”

Introduction ¶2Find in source

“Despite these promising results, there remains a lack of phase 3 confirmatory studies to further validate these findings.”

Introduction ¶2Find in source

“This preference for nab-paclitaxel, especially when combined with immunotherapy in LA-ESCC, is supported by several phase 2 studies”

Introduction ¶3Find in source

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial design is rigorous with clear randomization, stratification, and prespecified endpoints, though blinding is not applicable due to the open-label design.

Evidence

MethodsFind in source

Statistical analysisFind in source

“Moreover, the non-blinded design of this study could introduce some degree of bias.”

LimitationsFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous: randomized, stratified, with a prespecified sample size calculation, clear inclusion/exclusion criteria, and a defined analysis population.

Evidence

MethodsFind in source

Statistical analysisFind in source

“Moreover, the non-blinded design of this study could introduce some degree of bias.”

LimitationsFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables are well reported for a human trial, including sex, age, and clinical characteristics; species/strain and housing are not applicable.

Evidence

“The median age of all patients was 63 years (range, 44–75), with 84.9% being male.”

ResultsFind in source

“Median (range) | 63 (45–75) | 63 (44–75) | 65 (44–75)”

Table 1Find in source

“Among these patients, 6 (1.5%) were in clinical stage I (all cT1N1), 100 (25.6%) were stage II, 279 (71.4%) were stage III and 6 (1.5%) were stage IVA.”

ResultsFind in source

PASSReviewer 2· 90% conf

Sex, age, and clinical characteristics are reported in detail; demographics are comprehensive.

Evidence

paraphrase[Table 1]

“Sex, n (%) | Male | 116 (87.9) | 112 (86.2) | 104 (80.6)”

“The median age of all patients was 63 years (range, 44–75), with 84.9% being male.”

ResultsFind in source

paraphrase[Table 1]

“ECOG PS, n (%) | 0 | 105 (79.5) | 106 (81.5) | 104 (80.6)”

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals are thoroughly documented with named ethics committees and informed consent; regulatory compliance is implied.

Evidence

paraphrase[Methods, Study design and patients]

“All enrolled patients provided written informed consent.”

MethodsFind in source

“The study was registered before patient enrollment ( ChiCTR2000040034 (https://www.chictr.org.cn/showproj.html?proj=64180) ).”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethics approval from named committees and written informed consent are documented; trial registration is provided.

Evidence

paraphrase[Methods, Study design and patients]

“All enrolled patients provided written informed consent.”

MethodsFind in source

“Chinese Clinical Trial Registry identifier: ChiCTR2000040034”

AbstractFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Key resources are adequately identified: investigational drugs are named with doses, and the PD-L1 IHC kit is specified; software is identified.

Evidence

“The Cam+nab-TP group received camrelizumab (200 mg on day 1), albumin-bound paclitaxel (125 mg/m² on days 1 and 8), and cisplatin (75 mg/m² on day 1).”

MethodsFind in source

“PD-L1 expression levels at a central laboratory via immunohistochemistry (PD-L1 IHC 22C3 pharmDx kit, Dako).”

MethodsFind in source

“All statistical analyses were conducted using SAS software version 9.4.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational products (camrelizumab, paclitaxel, nab-paclitaxel, cisplatin) are identified with doses and regimens; PD-L1 IHC kit is specified.

Evidence

“The Cam+nab-TP group received camrelizumab (200 mg on day 1), albumin-bound paclitaxel (125 mg/m² on days 1 and 8), and cisplatin (75 mg/m² on day 1).”

MethodsFind in source

“PD-L1 expression levels at a central laboratory via immunohistochemistry (PD-L1 IHC 22C3 pharmDx kit, Dako).”

MethodsFind in source

“All statistical analyses were conducted using SAS software version 9.4.”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and confidence intervals; assumptions are handled by design.

Evidence

“The pCR between Cam+nab-TP and TP groups as well as between Cam+TP and TP groups were compared by using stratified Cochran-Mantel-Haenszel test with the same stratification factor.”

Statistical analysisFind in source

“P < 0.0001; Cam+TP versus TP: difference 10.9%, 95% CI 3.7–18.1, P = 0.0034”

ResultsFind in source

“difference 23.5%, 95% confidence interval (CI), 15.1–32.0; odds ratio (OR), 8.11; 95% CI, 3.28–20.06”

ResultsFind in source

PASSReviewer 2· 90% conf

Statistical tests are named, p-values are exact, effect sizes with CIs are reported, and software is identified; data presentation follows clinical trial norms.

Evidence

“The pCR between Cam+nab-TP and TP groups as well as between Cam+TP and TP groups were compared by using stratified Cochran-Mantel-Haenszel test”

Statistical analysisFind in source

“P < 0.0001; Cam+TP versus TP: difference 10.9%, 95% CI 3.7–18.1, P = 0.0034”

ResultsFind in source

“difference 23.5%, 95% confidence interval (CI), 15.1–32.0; odds ratio (OR), 8.11; 95% CI, 3.28–20.06”

ResultsFind in source

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is adequately described with a managed-access mechanism; code sharing is not applicable as no custom code was used.

Evidence

Data availabilityFind in source

“No custom code was used for data analysis in this study.”

Data availabilityFind in source

PASSReviewer 2· 90% conf

Data availability statement provides a concrete managed-access route; protocol and SAP are available; no custom code was used.

Evidence

Data availabilityFind in source

“The study protocol and statistical analysis plan are available alongside the published article.”

Data availabilityFind in source

“No custom code was used for data analysis in this study.”

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Reporting is transparent with detailed methods, trial registration, and discussion of limitations; reporting guideline adherence is implied but not explicitly stated.

Evidence

“Chinese Clinical Trial Registry identifier: ChiCTR2000040034”

AbstractFind in source

“This study has several limitations. First, this study did not directly compare the two neoadjuvant chemotherapy regimens combined with camrelizumab that were tested.”

LimitationsFind in source

paraphrase[Acknowledgements and Competing interests]

“This study was funded by Jiangsu Hengrui Pharmaceuticals. ... Z.H., R. Zheng and W.Z. are employees of Jiangsu Hengrui Pharmaceuticals.”

PASSReviewer 2· 90% conf

Methods are detailed, trial is registered, limitations are discussed, conclusions are proportional, and funding/COI are disclosed.

Evidence

“Chinese Clinical Trial Registry identifier: ChiCTR2000040034”

AbstractFind in source

“This study has several limitations. First, this study did not directly compare the two neoadjuvant chemotherapy regimens combined with camrelizumab that were tested.”

LimitationsFind in source

paraphrase[Acknowledgements and Competing interests]

“This study was funded by Jiangsu Hengrui Pharmaceuticals. ... Z.H., R. Zheng and W.Z. are employees of Jiangsu Hengrui Pharmaceuticals.”

Registered (2 IDs: ClinicalTrials.gov, Chinese Clinical Trial Registry). Reporting guideline cited: CONSORT.

Broken references and links

1 finding · worst low

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

Checked 51 references by DOI: 50 verified — 1 DOI unresolved.

2 data/code links checked; 2 live.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly clarity, grammar, consistency.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHreporting
Add an explicit statement of adherence to CONSORT reporting guidelines in the Methods or a dedicated Reporting Summary section.
Both reviewers noted that a reporting guideline is not explicitly mentioned, which is a standard expectation for a phase 3 trial.
2.
HIGHethics
Add a statement of regulatory compliance (e.g., Declaration of Helsinki) in the Methods section.
Both reviewers flagged that regulatory compliance is not explicitly stated, which is a minor but common reporting gap.
3.
HIGHreporting
Verify the reference 'Chinese Guidelines on Perioperative Management of Resectable Esophageal Cancer (2023 edition)' (DOI: 10.3760/cma.j.cn112137-20230604-00933) that was not found in the registry; correct or replace it if necessary.
A reference not found in any registry may be fabricated or have an incorrect DOI; this is a potential integrity concern.
4.
MEDIUMcopyedit
Remove the erroneous URL link to UniProt (https://www.uniprot.org/uniprot/T3N0M0) in the Methods, Study design and patients section.
The URL is irrelevant and likely a formatting error; it could confuse readers.
5.
MEDIUMcopyedit
Standardize the formatting of '95% CI' vs '95% confidence interval' throughout the manuscript (e.g., in the Abstract).
Minor formatting inconsistency that can be easily harmonized.
6.
MEDIUMcopyedit
Rephrase 'The impact of pCR varies across different neoadjuvant regimens' to 'The impact of pCR varies among different neoadjuvant regimens' in the Discussion.
Minor grammatical improvement for clarity.
7.
MEDIUMreporting
Clarify the manufacturer/source of camrelizumab in the Methods (e.g., Jiangsu Hengrui Pharmaceuticals).
One reviewer noted that the source of the investigational product is not explicitly stated in the text, though it is implied by the sponsor.
8.
MEDIUMreporting
Provide the specific version of the PD-L1 IHC 22C3 pharmDx kit and any validation data in the Methods.
One reviewer suggested improving key_resources reporting by including version and validation details.
9.
MEDIUMreporting
Add a statement on the handling of missing data for PD-L1 status (e.g., imputation or sensitivity analysis) in the Statistical analysis section.
One reviewer noted that missing data handling for PD-L1 is not addressed, which could affect subgroup analyses.
10.
LOWreporting
Consider providing a direct comparison between Cam+nab-TP and Cam+TP groups as a prespecified exploratory analysis to address the limitation noted in the Discussion.
The authors themselves note this as a limitation; a prespecified exploratory analysis would strengthen the paper.
11.
LOWreporting
In the Discussion, explicitly acknowledge that the pCR endpoint is a surrogate and that EFS/OS are needed to confirm clinical benefit.
One reviewer suggested making this point more prominent to temper conclusions.
12.
LOWdata code
Consider adding a data-sharing statement that includes an expected date for data availability (e.g., '24 months after study completion, expected by [date]').
One reviewer noted that the timeline is vague without a specific date.

Full text (64,505 chars)Analyzed: Aug 16, 2026